Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROAIR DIGIHALER vs ALA-SCALP
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Beta2-adrenergic receptor agonist; stimulates adenylate cyclase, increasing cyclic AMP (c AMP) in bronchial smooth muscle, resulting in bronchodilation.
ALA-SCALP (aminolevulinic acid) is a photosensitizer precursor that is converted intracellularly to protoporphyrin IX (Pp IX), which accumulates in cells with increased heme synthesis, such as rapidly dividing cells. Upon exposure to blue light (BLU-U®), Pp IX produces reactive oxygen species, leading to cellular damage and apoptosis of targeted cells.
FDA: Treatment or prevention of bronchospasm in patients with reversible obstructive airway disease (e.g., asthma),FDA: Prevention of exercise-induced bronchospasm
Treatment of minimally to moderately thick actinic keratoses of the scalp (Grade 1 or 2) in immunocompetent patients,Off-label: other photosensitivity disorders
90 mcg (2 inhalations) via oral inhalation every 4-6 hours as needed for bronchospasm. For exercise-induced bronchospasm, 180 mcg (2 inhalations) 15 minutes before exercise.
Topical application of a 5% solution to the scalp twice daily.
Terminal elimination half-life of albuterol (active ingredient) is 3.8-5.0 hours; clinical context indicates drug is rapidly cleared with no significant accumulation
Not applicable; topical ALA-SCALP is not significantly absorbed systemically. After systemic absorption from photodynamic therapy, terminal half-life is approximately 1 hour due to rapid metabolism.
Primarily metabolized by conjugation (sulfation) in the gastrointestinal tract and liver; minor CYP450 metabolism.
ALA is metabolized intracellularly via the heme biosynthesis pathway to protoporphyrin IX (Pp IX).
Renal: 60-70% of systemically absorbed dose excreted in urine as sulfate conjugate; biliary/fecal: minimal (approximately 10% unchanged); unchanged drug in urine: <2%
Primarily renal elimination of metabolites; <1% excreted unchanged in urine. Biliary/fecal excretion is negligible.
Approximately 10% bound to plasma proteins (primarily albumin)
Not characterized; systemic levels are negligible after topical administration.
Vd of albuterol is approximately 1.0-4.0 L/kg (mean 2.5 L/kg), indicating extensive distribution into tissues
Not applicable for topical route. If systemic exposure occurs, Vd is approximately 0.5 L/kg, consistent with distribution into total body water.
Inhalation: mean absolute bioavailability from a metered-dose inhaler is approximately 7% of the administered dose, though systemic exposure varies with inhaler technique
Topical: Systemic bioavailability is minimal (<1%) due to poor percutaneous absorption and rapid local metabolism.
No dose adjustment required for renal impairment. Albuterol is primarily hepatically metabolized and renally excreted as metabolites; however, no specific GFR-based guidelines exist.
No dose adjustment required for renal impairment.
No specific dose adjustment recommended for hepatic impairment. Use with caution in severe hepatic impairment due to potential accumulation; monitor for adverse effects.
No dose adjustment required for hepatic impairment.
Children 4-11 years: 90-180 mcg (1-2 inhalations) every 4-6 hours as needed. For exercise-induced bronchospasm: 90-180 mcg 15 minutes before exercise. Weight-based dosing not typically used; follow age-based guidelines.
Safety and efficacy in pediatric patients have not been established.
No specific dose adjustment required. Use lowest effective dose due to potential increased sensitivity and comorbidities. Monitor for tachycardia, tremor, and hypertension.
No specific dose adjustment recommended; use with caution due to potential increased sensitivity.
No FDA black box warning.
No FDA black box warning.
Paradoxical bronchospasm with fatal outcomes; discontinue immediately if occurs,Life-threatening asthma exacerbations; need for increased use may indicate worsening asthma,Cardiovascular effects: increased heart rate, hypertension, arrhythmias; use with caution in patients with cardiovascular disorders,Hypokalemia and hyperglycemia; monitor serum potassium and glucose in susceptible patients,Rare anaphylactic reactions,Do not exceed recommended dose; excessive use may lead to death
Photosensitivity: avoid exposure to sunlight or bright indoor light (e.g., examination lamps, operating room lamps) for at least 40 hours post-application.,Application site reactions: severe stinging, burning, erythema, and edema may occur.,Use sun-protective measures (e.g., wide-brimmed hat, sunscreen) after treatment.,Do not apply to eyes or mucous membranes.
Hypersensitivity to albuterol or any component of the product
Hypersensitivity to aminolevulinic acid or any component of the formulation,Cutaneous photosensitivity at wavelengths of 400-450 nm,Porphyria
No specific food-drug interactions are known for albuterol. However, caffeine-containing foods and beverages (coffee, tea, cola, energy drinks) may potentiate the stimulant effects (e.g., tachycardia, tremor). Hypokalemia may be potentiated by concurrent use of potassium-depleting diuretics or prolonged use. Avoid high-sulfite foods if a sulfite sensitivity is present, as these may trigger bronchospasm in some asthmatics.
No known food interactions. No dietary restrictions required.
Albuterol sulfate, the active ingredient in PROAIR DIGIHALER, is generally considered low risk during pregnancy. Animal studies have shown no evidence of teratogenicity at clinically relevant doses. In humans, inhaled beta-agonists are not associated with an increased risk of major congenital malformations. However, maternal asthma exacerbations pose significant risks to the fetus, including preterm birth and low birth weight. Therefore, the benefit of controlled asthma outweighs the theoretical risks. First trimester exposure is not linked to increased malformation rates. Second and third trimester use is considered safe, with no known fetal toxicity at standard doses. No specific teratogenic risk profile by trimester is established.
No evidence of teratogenicity; topical application with minimal systemic absorption. First trimester: unlikely risk. Second/third trimester: no known fetal risks from maternal use.
Albuterol is excreted into breast milk in small amounts. The milk-to-plasma (M/P) ratio is approximately 2.5, but the infant dose is estimated to be less than 1% of the maternal dose. Due to low oral bioavailability, significant infant exposure is unlikely. However, observe the infant for signs of beta-adrenergic stimulation (e.g., tachycardia, irritability). The benefit of maternal asthma control generally outweighs the minimal risk to the breastfed infant.
Minimal systemic absorption; unlikely to appear in breast milk. M/P ratio not established. Considered compatible with breastfeeding.
Pharmacokinetic changes in pregnancy (increased plasma volume, renal clearance) may lead to lower serum concentrations of albuterol. However, clinical effectiveness typically remains sufficient. No routine dose adjustments are recommended; dosing should be guided by symptom control. In severe asthma exacerbations during pregnancy, higher doses or more frequent administration may be required. Monitor for maternal tachycardia and hypokalemia.
No dosage adjustment required; pharmacokinetics unlikely altered due to topical route.
PROAIR DIGIHALER contains albuterol sulfate, a short-acting beta-2 agonist (SABA). It is indicated for the treatment or prevention of bronchospasm in patients aged 4 years and older with reversible obstructive airway disease, and for the prevention of exercise-induced bronchospasm (EIB). The device is breath-activated, requiring a low inspiratory flow rate (approx. 20 L/min) for optimal dose delivery. Shake well before each use. Priming is not needed for new inhalers if used within 2 weeks; if not used for more than 2 weeks, prime by releasing 1 test spray into the air. Rinse mouth with water after each use to reduce risk of oropharyngeal candidiasis. Avoid concomitant use of non-selective beta-blockers (e.g., propranolol) as they may antagonize bronchodilatory effects. Monitor for paradoxical bronchospasm, tachycardia, and hypokalemia. Not for acute severe asthma exacerbation requiring intensive care; use a nebulized SABA or IV bronchodilator instead.
ALA-SCALP is a topical aminolevulinic acid preparation used for photodynamic therapy of actinic keratoses on the scalp. Must be applied by a healthcare professional. Avoid sun exposure to treated area for 48 hours post-application due to photosensitivity. Do not apply to eyes or mucous membranes. Lesions should be prepped by gentle removal of scales and crusts. Use with a compatible light source (blue light). Burning and stinging during light exposure is common; consider pain management strategies.
Use exactly as prescribed; do not exceed recommended doses.,Shake the inhaler well before each use.,Exhale fully, place mouthpiece between lips, inhale deeply and forcefully to activate the dose; hold breath for 10 seconds, then exhale slowly.,Rinse mouth with water after each use to prevent mouth and throat irritation.,Do not use if the inhaler has been dropped or damaged; check dose counter regularly.,Seek emergency medical attention if breathing problems worsen despite using this medication.,Avoid foods or beverages that may trigger asthma symptoms, such as sulfites (e.g., dried fruits, wine).,Avoid caffeine (coffee, tea, soda) as it may increase side effects like nervousness and rapid heartbeat.,Stay hydrated but avoid large amounts of cold water immediately before or after use.
This medication is applied by your doctor to treat precancerous spots on your scalp.,After application, you will need a special light treatment (photodynamic therapy).,Avoid sunlight and bright indoor light on the treated area for 48 hours after the procedure.,You may experience temporary redness, swelling, scaling, or discomfort at the treatment site.,Use sunscreen and protective clothing when going outdoors during the photosensitivity period.,Do not wash the treated area for at least 4 hours after the solution is applied.,Contact your doctor if you experience severe pain, blistering, or signs of infection.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROAIR DIGIHALER vs ALA-SCALP, answered by our medical review team.
PROAIR DIGIHALER is a Beta-2 Agonist Bronchodilator that works by Beta2-adrenergic receptor agonist; stimulates adenylate cyclase, increasing cyclic AMP (c AMP) in bronchial smooth muscle, resulting in bronchodilation.. ALA-SCALP is a Topical Corticosteroid that works by ALA-SCALP (aminolevulinic acid) is a photosensitizer precursor that is converted intracellularly to protoporphyrin IX (Pp IX), which accumulates in cells with increased heme synthesis, such as rapidly dividing cells. Upon exposure to blue light (BLU-U®), Pp IX produces reactive oxygen species, leading to cellular damage and apoptosis of targeted cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROAIR DIGIHALER and ALA-SCALP depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROAIR DIGIHALER is: 90 mcg (2 inhalations) via oral inhalation every 4-6 hours as needed for bronchospasm. For exercise-induced bronchospasm, 180 mcg (2 inhalations) 15 minutes before exercise.. The standard adult dose of ALA-SCALP is: Topical application of a 5% solution to the scalp twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROAIR DIGIHALER and ALA-SCALP in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROAIR DIGIHALER is classified as Category C. Albuterol sulfate, the active ingredient in PROAIR DIGIHALER, is generally considered low risk during pregnancy. Animal studies have shown no evidence of teratogenicity at clinical. ALA-SCALP is classified as Category C. No evidence of teratogenicity; topical application with minimal systemic absorption. First trimester: unlikely risk. Second/third trimester: no known fetal risks from maternal use.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.